GlassScriptPhysician profile
Ambreen Ahmed
NPI 1376655746
$2,230.45
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $324 · 2022: $676 · 2023: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $109.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $520.94 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $305.71 | 2019-2023 | Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $283.42 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $230.39 | 2019-2022 | |
| Alkermes, INC. | $199.03 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $179.60 | 2022-2023 | Austedo |
| Avanir Pharmaceuticals, INC. | $81.82 | 2022 | |
| Abbvie INC. | $68.87 | 2022-2023 | Vraylar |
| Indivior INC. | $60.84 | 2020-2023 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.85 | 2022 | |
| Shire North American Group INC | $59.74 | 2019 | |
| Ironshore Pharmaceuticals INC. | $48.11 | 2019-2020 | |
| Corium, LLC | $40.29 | 2022-2023 | Azstarys |
| Lundbeck LLC | $35.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.23 | 2019-2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $23.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambreen Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.